CStone, a Suzhou biopharma, has dosed the first patient in the China arm of a global Phase I registrational study of BLU-667, a RET-inhibitor, in patients with various solid tumor cancers. One year ago, CStone in-licensed greater China rights to BLU-667 as part of a $386 million deal for three Blueprint oncology candidates. Blueprint has already started the global Phase I ARROW trial, which will evaluate the overall response rate, duration of response, pharmacokinetics, pharmacodynamics and safety of BLU-667 in NSCLC and other cancers. Source: China Biotoday
